Achillion Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue - 2,607 247 2,436
Cost of Revenue - - - -
Gross Profit - 2,607 247 2,436
Operating Expenses
Research and Development 46,736 38,999 35,441 20,529
Sales, General and Admin. 12,741 10,901 9,153 7,205
Non-Recurring Items - - - -
Other - - - -
Operating Income (59,477) (47,293) (44,347) (25,298)
Income From Continuing Operations
Add'l Income/Expense Items 582 234 186 101
Earnings Before Interest and Tax (58,895) (47,059) (44,161) (25,197)
Interest Expense 52 68 45 284
Earnings Before Tax (58,947) (47,127) (44,206) (25,481)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (58,947) (47,127) (44,206) (25,481)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (58,947) (47,127) (44,206) (25,481)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (58,947) (47,127) (44,206) (25,481)